Meet the Team

The Team

The HiLo study team is
committed to generating evidence on how best to manage blood phosphate levels in people with kidney failure on dialysis. The team consists of patient ambassadors, nephrologists, dietitians, facility managers, scientists, and clinical research professionals.

What is the best blood level of phosphate for people with kidney failure on dialysis?

Meet The Team

The HiLo study team is committed to generating evidence on how best to manage blood phosphate levels in people with kidney failure on dialysis. The team consists of patient ambassadors, nephrologists, dietitians, facility managers, scientists, and clinical research professionals

“It is gratifying to be a part of this remarkable collaboration between government, industry, academia, patients, and clinician-scientists to shed light on one of the key unanswered questions in the care of patients receiving hemodialysis.”

Geoffrey Block, MD,
HiLo Steering Committee Member
Denver Nephrology

Susan Mendley, MD

Program Director, NIH/NIDDK
Bethesda, MD

"There is a lot that we don’t know about how to provide the best care to patients with chronic kidney disease and those who are receiving dialysis. Researchers are better able to answer important questions, like the best treatment target for serum phosphorus in dialysis, when they collaborate with patients."

Andrew Narva, MD

Program Director, NIH/NIDDK
Bethesda, MD

Tamara Isakova, MD

Co-Investigator, Northwestern Univ.
Chicago, IL

Daniel Edmonston, MD

Steering Committee, DCRI 
Durham, NC 

"The status quo of kidney care is often based on a house of cards of low-quality, small-scale, observational data. HiLo has a chance to gather quality evidence to answer an issue which affects all hemodialysis patients. This study also heralds a new focus on pragmatic trial designs in nephrology with real-world inclusion criteria and generalizable data."

Kelsey Bludorn

Dialysis Partner, DaVita Clinical Research
Minneapolis, MN

"This study provides a valuable look at the practice of managing phosphate levels which could potentially lead to changes improving the quality of ESRD patients' lives. That's something we'd all love to see."

Peter Merrill, PhD

Researcher, DCRI
Durham, NC

"HiLo is a chance to use the strength of a randomized clinical trial to answer an outstanding question about dialysis treatment. The results of the trial will allow dialysis providers to better treat their patients."

Yashika Johnson, BA, MA

Clinical Research Associate, DCRI
Durham, NC

"The information we learn over the course of this trial will help us better understand the best phosphate levels for patients on dialysis and lead to improvements in current healthcare practice guidelines and recommendations for those patients."

Andy Mackelfresh, BS, MBA

Technology & Data Solutions Project Leader, DCRI
Durham, NC

"This is an excellent study challenging the standard of care for phosphate levels within patients receiving dialysis."

Laura Dember, MD

Co-Investigator, University of Pennsylvania
Philadelphia, PA

"HiLo addresses a question that patients and kidney professionals face every day: What is the best target for phosphate levels in the blood? And by incorporating the trial into the real-world setting of clinical care delivery we can be confident that the results will be relevant and applicable to the broad population of patients being treated with hemodialysis."

Amy Young

Steering Committee Member, DaVita Clinical Research
Minneapolis, MN

"HiLo is an important study for people with end stage renal disease because it is focused on the guidelines for treatment. Many guidelines are developed when experts combine data and evidence from other studies. This study will directly ask which clinical targets are better for overall life expectancy and hospitalization rates. Since phosphorus binders are a significant contributor to the pill burden for people on dialysis this study will also help support clinical choices with medications."

Davy Andersen, MHA

Project Leader, DCRI
Durham, NC

"It is critical that we provide an empirical evidence-based approach to how we treat patients with ESRD while also providing the greatest quality of life
possible."

Laura Johnson, MHS, PMP

Project Leader, DCRI
Durham, NC

"Patients deserve to know that the treatments and care they are receiving is the most appropriate, up-to-date option for them. The Duke Clinical Research Institue is constantly striving to learn more and do more for patients. HiLo is a part of that drive to serve patients."

James Topping, MS

Informaticist, DCRI
Durham, NC

"HiLo is great example of the new frontier of clinical research- leveraging existing data collection to answer important clinical questions in an empirical, data-driven manner."

Lisa Garner

Patient Ambassador
Conway, AR